Subcutaneous DMPA Access Collaborative
Expanding contraceptive access and options in 8 to 12 countries
Between 2017 and 2020, the newly formed Subcutaneous DMPA Access Collaborative, led by PATH and John Snow Inc. (JSI), will work with ministries of health and partners in 8 to 12 countries to facilitate planning for introduction and scale up of subcutaneous DMPA (DMPA-SC, marketed as Pfizer’s Sayana® Press). The Access Collaborative will provide technical assistance to ensure implementation of each country’s total market plan.
Initial focal countries are likely to include Burkina Faso, Democratic Republic of the Congo, Kenya, Madagascar, Mozambique, Niger, Nigeria, Senegal, Uganda, and Zambia, contingent on local interest. The project will also help mobilize resources by raising awareness of relevant funding gaps among donors.
In addition, the Access Collaborative will facilitate learning within and beyond the 8 to 12 countries by exchanging information, results, and lessons learned; troubleshooting challenges; and accelerating the adoption of best practices through an interactive, virtual network.
For further information about the Access Collaborative, please contact us.
Subcutaneous DMPA: Evidence, experience, and resources for introduction (2017)
During this webinar hosted by PATH and JSI on October 3, 2017, presenters provided an overview of tools, resources, and references for DMPA-SC introduction planning and implementation, as well as self-injection program design.
Presenters also discussed the Access Collaborative’s forthcoming work with ministries of health and partners to facilitate introduction and scale-up.